Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2016 Feb;17(3):231-40.
doi: 10.2217/pgs.15.162. Epub 2016 Jan 22.

Evidence for association of SNPs in ABCB1 and CBR3, but not RAC2, NCF4, SLC28A3 or TOP2B, with chronic cardiotoxicity in a cohort of breast cancer patients treated with anthracyclines

Daniel L Hertz  1 , Megan V Caram  2 , Kelley M Kidwell  3 , Jacklyn N Thibert  2 , Christina Gersch  2 , Nicholas J Seewald  3 , Jeffrey Smerage  2 , Melvyn Rubenfire  4 , N Lynn Henry  2 , Kathleen A Cooney  2   5 , Monika Leja  4 , Jennifer J Griggs  2 , James M Rae  2   6
Affiliations
Observational Study

Evidence for association of SNPs in ABCB1 and CBR3, but not RAC2, NCF4, SLC28A3 or TOP2B, with chronic cardiotoxicity in a cohort of breast cancer patients treated with anthracyclines

Daniel L Hertz et al. Pharmacogenomics. 2016 Feb.

Abstract

Aims: Validation of associations for SNPs in RAC2, NCF4 and SLC28A3, identification of a novel association with a TOP2B SNP and screening 23 SNPs putatively relevant to anthracycline-induced cardiotoxicity.

Patients & methods: A total of 166 breast cancer patients treated with doxorubicin underwent echocardiogram, including 19 cases with systolic dysfunction (ejection fraction <55%) and 147 controls. Four high priority SNPs were tested in the primary analysis, with appropriate statistical correction, and 23 additional SNPs were screened in an uncorrected secondary analysis.

Results: Previously reported associations for RAC2, NCF4 and SLC28A3 could not be validated and a novel association with TOP2B was not discovered in this cohort (all p > 0.05), likely due to inadequate power. Two SNPs were identified in the uncorrected secondary analysis including a protective SNP in ABCB1 (3435C>T, p = 0.049) and a risk allele in CBR3 (V244M, p = 0.012).

Conclusion: The associations reported in prior publications and those discovered in this secondary analysis require further replication in independent cohorts.

Keywords: ABCB1; CBR3; NCF4; RAC2; SLC28A3; TOP2B; anthracycline; cardiotoxicity; doxorubicin; pharmacogenetic; systolic dysfunction.

PubMed Disclaimer

Conflict of interest statement

Financial & competing interests disclosure

This work was supported in part by The Breast Cancer Research Foundation (BCRF) (N003173 to JM Rae), the NIH (1RO1GM099143 to JM Rae), by a Pfizer Foundation Fellowship Award awarded to K Cooney to support M Caram, by the University of Michigan Cancer Research Committee Research Grant awarded to J Smerage and by the National Cancer Institute of the NIH under Award Number P30CA046592 by the use of the following Cancer Center Core: UM DNA Sequencing Core. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

Figures

<b>Figure 1.</b>
Figure 1.. Flowchart of patients from enrollment into the parent study to classification of cases and controls for this pharmacogenetic analysis.
Among the 293 patients enrolled on the clinical study, 166 underwent an echocardiogram, 19 of which were documented to have EF <55% (cases). Patients with normal echocardiograms (EF ≥55%; n = 147) were included as controls. CHF: Congestive heart failure; EF: Ejection fraction determined by transthoracic echocardiogram.
<b>Figure 2.</b>
Figure 2.. Association of SNPs in ABCB1 and CBR3 with systolic dysfunction.
Two SNPs were significantly associated with systolic dysfunction (EF <55%) in the secondary pharmacogenetic screen of 23 candidate SNPs. The ABCB1 3435C>T variant (rs1045642, Figure 2A) was more common in controls than systolic dysfunction cases, providing an additive protective effect (odds ratio [OR] = 0.48; 95% CI: 0.23–1.00; p = 0.049). The CBR3 V244M (rs1056892, Figure 2B) SNP was found more often in cases than controls, with significantly increased risk in either an additive (OR = 2.50; 95% CI: 1.22–5.11; p = 0.012) or recessive (OR = 6.19; 95% CI: 1.94–19.76; p = 0.002) genetic model. Note: Numbers do not add up to 166 due to missing genotypes in some patients (ABCB1: 4; CBR3: 3). EF: Ejection fraction.
See this image and copyright information in PMC

References

    1. Fumoleau P, Roche H, Kerbrat P, et al. Long-term cardiac toxicity after adjuvant epirubicin-based chemotherapy in early breast cancer: French Adjuvant Study Group results. Ann. Oncol. 2006;17(1):85–92. - PubMed
    1. Perez EA, Suman VJ, Davidson NE, et al. Effect of doxorubicin plus cyclophosphamide on left ventricular ejection fraction in patients with breast cancer in the North Central Cancer Treatment Group N9831 Intergroup Adjuvant Trial. J. Clin. Oncol. 2004;22(18):3700–3704. - PubMed
    1. Sawaya H, Sebag IA, Plana JC, et al. Early detection and prediction of cardiotoxicity in chemotherapy-treated patients. Am. J. Cardiol. 2011;107(9):1375–1380. - PMC - PubMed
    1. Ganz PA, Hussey MA, Moinpour CM, et al. Late cardiac effects of adjuvant chemotherapy in breast cancer survivors treated on southwest oncology group protocol S8897. J. Clin. Oncol. 2008;26(8):1223–1230. - PubMed
    1. Zambetti M, Moliterni A, Materazzo C, et al. Long-term cardiac sequelae in operable breast cancer patients given adjuvant chemotherapy with or without doxorubicin and breast irradiation. J. Clin. Oncol. 2001;19(1):37–43. - PubMed

Publication types

MeSH terms

LinkOut - more resources